🔗 Share this article

An senior medical figure has been recused of participation in a significant research project into puberty blockers subsequent to accusations of bias came to light.

Alleged Intervention Resulted in Study Pause

As reported by news accounts, Professor Jacob George, the head medical and scientific officer for the regulatory agency, expressed issues that caused the suspension of a national research initiative in February.

The agency stated recently that George had recused him from any role with the trial after gender-critical online remarks posted last year were identified.

Content Regarding the Online Posts

Among a post, he referred to writer J.K. Rowling as an asset of our time.” Elsewhere, the professor stated that “the denial of basic biological fact is worrisome” in relation to questions over an Olympic boxer’s sex.

This agency clarified that even though the comments occurred before his appointment, the official had been recused from involvement with the study as a preventative measure.

Particulars of the Halted Clinical Study

The Pathways trial, which was designed to study the effect of hormone suppressants for young people questioning their gender, was set to begin recruiting volunteers in January.

But, the trial was suspended in February when its regulatory body raised worries about the wellbeing of adolescents involved.

• The youngest subjects were anticipated to start at ten to eleven for assigned female at birth while 11 to 12 for biological males.
• Its trial team stated at the time that the thorough screening process indicated those enrolled would likely be older.
• But, officials have since said the minimum age threshold ought to be 14 due to an unknown danger” for enduring physical side effects.”

This research was designed to recruit around 226 adolescents over the following several years.

Context and the Cass Review

The study was commissioned after a suggestion from the Cass review into children’s gender care, which determined how the quality of studies suggesting to show the positive effects from this type of medication for adolescents with gender incongruence were “poor.”

Dr Hilary Cass, who headed the report, has previously said her report revealed a notably limited scientific foundation” for the usefulness of puberty blockers.

Dr. Cass continued, “given that there exist clinicians, young people and parents who believe passionately in the positive outcomes, research remained the necessary step ahead to make sense of the situation.”

Medical Concern Regarding the Action

Dr Max Davie, a child health specialist, argued there was no convincing scientific reason to suspend the study.

“The tweets from Professor George provide a clear indication into his own opinions on this issue,” he remarked. “The professor is free to possess any opinions about this subject he may, however what is improper would be to permit these views to affect the fulfilment of his official role.”

The doctor added: “For clarity, there is no persuasive scientific reason to halt this study. While the professor’s individual beliefs are not the only potential reason of the MHRA’s unexpected reversal, it are the single factor for which evidence.”

Agency Statement and Next Steps

An regulatory representative commented: “In all clinical trials, our primary concern remains the protection as well as wellbeing of those involved. In line with this duty, detailed clinical trials are kept continuously being monitored and the agency maintains a continuous discussion alongside trial sponsors.”

“The MHRA has expert scientific, medical and oversight specialists that operate in a multidisciplinary team to make research-informed decisions on clinical trials. These individuals shall persist to engage with the research team to address the future path productively.”

“Subsequent to the finding of social media activity posted before he took up his role, Prof Jacob George is recused of continued oversight with this clinical trial as an precaution.”